{
}
Muna Therapeutics has partnered with GSK to explore new Alzheimer’s drug targets by analyzing brain tissue samples from various sources, including healthy individuals and Alzheimer’s patients. GSK will invest €33.5 million upfront, with potential milestone payments of up to €140 million for each target identified. This collaboration marks GSK's renewed focus on neuroscience after a decade-long hiatus, leveraging Muna's technology to advance drug development in neurodegenerative diseases.
Rita J Balice-Gordon
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
GSK Partners with Muna Therapeutics to Advance Alzheimer's Drug Development
01:00 05.12.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Finance Mergers & Acquisitions
Global Financial Events
Banking Regulations
Retail and Consumer Goods
Market Analysis and Predictions
CEO Changes
Global Trade Developments
Industry Mergers & Acquisitions
Energy Sector Developments
Startups & Entrepreneurship
Supply Chain Management
Financial Scams and Security
Government Policies
Central Bank Actions
Government Economic Policies
Domestic Politics
Workplace Trends
Countries:
Companies:
Tesla, Inc.
Barclays PLC
BNP Paribas SA
JPMorgan Chase & Co.
Apple Inc.
Raiffeisen Bank International AG
Deutsche Bank RV Global PP
Bank of America Corporation
UBS Group AG
NVIDIA Corporation
Morgan Stanley
Capital One Financial Corporation
The Goldman Sachs Group, Inc.
Citigroup Inc.
Berkshire Hathaway Inc.
Amazon.com, Inc.
SpaceXCoin USD
Commerzbank AG
Credit Suisse Real Estate Fund Siat
Wells Fargo & Company
Currencies:
United States Dollar
Euro
Chinese Yuan
Swiss Franc
Indian Rupee
British Pound Sterling
Vietnamese Đồng
Japanese Yen
Australian Dollar
Hong Kong Dollar
United Arab Emirates Dirham
Russian Ruble
Singapore Dollar
South Korean Won
Thai Baht
Norwegian Krone
Danish Krone
Swedish Krona
Ghanaian Cedi
Canadian Dollar
People: